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ABSTRACT
Metastasis is the cause of most prostate cancer (PCa) deaths and has been
associated with circulating tumor cells (CTCs). The presence of ≥5 CTCs/7.5mL of
blood is a poor prognosis indicator in metastatic PCa when assessed by the CellSearch®
system, the “gold standard” clinical platform. However, ~35% of metastatic PCa
patients assessed by CellSearch® have undetectable CTCs. We hypothesize that
this is due to epithelial-to-mesenchymal transition (EMT) and subsequent loss of
necessary CTC detection markers, with important implications for PCa metastasis. Two
pre-clinical assays were developed to assess human CTCs in xenograft models; one
comparable to CellSearch® (EpCAM-based) and one detecting CTCs semi-independent
of EMT status via combined staining with EpCAM/HLA (human leukocyte antigen).
In vivo differences in CTC generation, kinetics, metastasis and EMT status were
determined using 4 PCa models with progressive epithelial (LNCaP, LNCaP-C42B)
to mesenchymal (PC-3, PC-3M) phenotypes. Assay validation demonstrated that
the CellSearch®-based assay failed to detect a significant number (~40-50%) of
mesenchymal CTCs. In vivo, PCa with an increasingly mesenchymal phenotype shed
greater numbers of CTCs more quickly and with greater metastatic capacity than
PCa with an epithelial phenotype. Notably, the CellSearch®-based assay captured the
majority of CTCs shed during early-stage disease in vivo, and only after establishment
of metastases were a significant number of undetectable CTCs present. This study
provides important insight into the influence of EMT on CTC generation and subsequent
metastasis, and highlights that novel technologies aimed at capturing mesenchymal
CTCs may only be useful in the setting of advanced metastatic disease.

overall survival [3–6], with ≥5 CTCs/7.5ml of blood being
indicative of poor prognosis in metastatic PCa patients
[6]. Additionally, changes in CTC number throughout
treatment have been demonstrated to reflect therapy
response [7].
Due to the rare nature of CTCs (~1 CTC/105-107
leukocytes in metastatic patients), extremely sensitive
technologies are required for accurate CTC detection
[8]. Several techniques have been employed to enrich

INTRODUCTION
Prostate cancer (PCa) is the most commonly
diagnosed cancer and second most common cause of
cancer death in American men [1]. The majority of
prostate cancer deaths result from metastasis, since current
therapies are non-curative in the metastatic setting [2].
Detection of circulating tumor cells (CTCs) in the blood
is correlated with metastatic disease burden and reduced
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CTCs including size- and/or density-based separation,
and antibody-based techniques with/without the aid of
microfluidics, while detection techniques rely almost
exclusively on protein- (immunofluorescence/flow
cytometry) or nucleic acid-based (RT-PCR/qRT-PCR)
assays [9, 10]. Each approach has unique advantages and
disadvantages; however most lack the standardization
and quality control required for routine clinical use. The
CellSearch® system (CSS; Janssen Diagnostics) provides
a standardized method for sensitive detection and
quantification of CTCs in human blood. It is the only CTC
assay approved by the U.S. Food and Drug Administration
for clinical management of metastatic prostate, breast, and
colon cancer patients [4–6], and is thus considered the
“gold standard” CTC platform.
The CSS distinguishes CTCs from leukocytes
through immunomagnetic selection of cells with an
EpCAM+ (epithelial cell adhesion molecule) phenotype
followed by differential fluorescent staining for
cytokeratins (CK) 8/18/19, CD45 (leukocyte marker),
and DNA (4’,6-diamidino-2-phenylindole [DAPI]).
Although the CSS has been used to effectively enumerate
CTCs in the blood of metastatic PCa patients [6], CTCs
are undetectable in ~30% of these patients despite the
presence of systemic disease [11]. This suggests that
either CTCs are truly not present in ~1/3 of metastatic PCa
patients; or that CTCs are present but undetectable by the
CSS because they do not meet the standard CTC definition
(EpCAM+/CK+/DAPI+/CD45-). It has been proposed
that this lack of detection may be due to the epithelialto-mesenchymal transition (EMT) [12–14], a dynamic
cellular process that leads to downregulation of epithelial
markers necessary for CTC capture/enumeration,
including EpCAM/CK [12, 15, 16]. Corresponding
increases in mesenchymal markers (N-cadherin/vimentin/
fibronectin) and resulting changes in cellular morphology
have been shown to enhance cancer invasion, metastasis,
therapy resistance, and disease aggressiveness [12, 17].
The standard CSS definition of CTCs may therefore be
missing the most invasive and highly metastatic cells
driving disease progression. In support of this, several
studies have demonstrated that CTCs with a purely
mesenchymal phenotype are undetectable by the CSS,
but that the presence of mesenchymal marker expression
on CTCs with a hybrid epithelial-mesenchymal (E-M)
phenotype is indicative of poor prognosis [15, 18–21].
This suggests that current clinical CTC assays may be
limiting our ability to capitalize on the full potential of
CTCs, and that a greater understanding of CTC biology is
necessary in order to guide future technology development
and translation to the clinic.
The field of CTC research is quite unique in that
it has evolved using a “bedside-to-bench” path rather
than the more traditional “bench-to-bedside” model of
translational research. Although this has allowed for
quick entry of CTC technology into the clinic, outstanding
www.impactjournals.com/oncotarget

questions regarding the biology of CTCs has resulted in
a hesitance for their widespread adoption as biomarkers
for directing patient care. Unfortunately, appropriate
experimental tools needed to address these outstanding
biology questions have been largely lacking, especially
those that mimic the approach utilized by the clinicallyused CSS. This highlights the need for implementation
of suitable pre-clinical models and development of
complementary CTC analysis techniques that can assess
not only the CTCs which are captured using the CSS
but also those that may be missed, in order to advance
knowledge. Previous work investigating CTC biology
in our laboratory using orthotopic xenograft models
demonstrated that CTC dissemination occurs relatively
early in the metastatic cascade and that CTCs can be
generated by both primary tumors as well as metastases
[22–24]. However, very little is currently known about the
functional role of EMT in CTC generation, detection and
metastasis, particularly in the context of prostate cancer.
In this study, we hypothesized that the EpCAMbased CSS assay is unable to detect CTCs that have
undergone EMT, and that EMT-related phenotypic
differences in CTCs have important implications for PCa
disease progression. To test this, we developed two preclinical assays for assessing human CTCs in xenograft
models; one that is comparable to the EpCAM-based CSS
(dependent on EMT status) and one that detects CTCs
semi-independent of EMT status via negative depletion
of CD45 and combined staining with EpCAM and HLA
(human leukocyte antigen). Using these assays, differential
in vivo CTC generation, capture efficiency, kinetics and
metastasis were assessed using 4 human PCa cell lines
(LNCaP, LNCaP C4-2B, PC-3, PC-3M) of increasing
aggressiveness in pre-clinical orthotopic models of PCa.
The novel results presented here provide functional
evidence of the interplay between EMT and CTC biology,
shedding light on which CTCs are the most important to
study. This knowledge has the potential to inform ongoing
CTC technology development and guide strategies for
the most effective use of CTCs as prognostic/predictive
biomarkers in clinical oncology.

RESULTS
Human PCa cell lines display differences in
EMT phenotype
Four human PCa cell lines (LNCaP, LNCaP C4-2B
[C4-2B], PC-3, PC-3M) previously reported to have
progressively increasing metastatic capacity [25–28]
were characterized for epithelial (E-cadherin/EpCAM/
CK) and mesenchymal (N-cadherin/vimentin) markers
using qRT-PCR, immunoblotting (Supplementary Figure
S1A, 1B), and flow cytometry (FCM) (Figure 1A). LNCaP
and C4-2B had consistently higher protein expression
of epithelial-associated markers E-cadherin and
76126
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CK8/18/19, while PC-3 and PC-3M had consistently
higher protein expression of mesenchymal-associated
markers N-cadherin and vimentin. Although EpCAM
levels appeared similar between cell lines at the mRNA

level (Supplementary Figure S1A), differences in EpCAM
protein expression were evident, with LNCaP and C4-2B
demonstrating higher levels compared to PC-3 and PC3M (Supplementary Figure S1B, Figure 1A). To further

Figure 1: Human prostate cancer cell lines display differences in EMT phenotype. A. Protein expression analysis by flow

cytometry for the epithelial-associated markers E-cadherin and EpCAM and the mesenchymal-associated markers N-cadherin and vimentin
in PC-3M, PC-3, LNCaP C4-2B, and LNCaP human prostate cancer cells. Data are presented as relative fluorescence intensity (expression)
compared to appropriate positive control cell lines (E-cadherin/EpCAM/CK: MDA-MB-468; N-cadherin/vimentin: HeLa) (n=3). The
expression of epithelial-associated and mesenchymal-associated proteins corresponds to previously reported cell aggressiveness and in vivo
metastatic capacity of these cell lines. B. Flow cytometry dot plots of the differential expression of EpCAM (AF488) and CK8/18/19 (PE)
in investigated prostate cancer cell lines. C. Flow cytometry analysis for co-expression of EpCAM and CK8/18/19, presented as the mean
± SEM fluorescence intensity of the investigated proteins for each cell line (n=3).
www.impactjournals.com/oncotarget
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investigate potential capacity for capture of these cells by
the EpCAM- and CK-reliant CSS, protein co-expression
was assessed using FCM (Figure 1B, 1C). This further
confirmed differential EpCAM expression between cell
lines, but interestingly demonstrated a similar distribution
of CK8/18/19 expression, suggesting that any differences
in CTC capture between cell lines would be due to
differences in EpCAM expression rather than CK8/18/19.
The ability of E-cadherin to maintain the epithelial
phenotype and normal adhesive function of cells is
dependent on its localization to the cell membrane
[29, 30]. We observed that that although E-cadherin was
expressed in PC-3, it was aberrantly localized to the
cytoplasm, likely due to a lack of α-catenin expression
which is necessary for appropriate E-cadherin membrane
localization [31]. In contrast, LNCaP and C4-2B strongly
expressed E-cadherin with appropriate membrane
localization (Supplementary Figure S2).

when using the same reagents and highly epithelial cells
(C4-2B), addition of extra processing steps resulted in
equivalent sample loss between matched samples when
comparing both assays (Supplementary Figure S3C).

Prostate cancer cell lines with an increasingly
mesenchymal phenotype have an enhanced
capacity for CTC shedding in vivo and produce
CTCs that are undetectable by the CSS
LNCaP, C4-2B, PC-3, and PC-3M cells prepared in
Hank’s buffered saline were injected (1x106 cells/40μL per
mouse) orthotopically via the right dorsolateral lobe of the
prostate as described in the Materials and Methods in order
to assess in vivo CTC generation, kinetics, and detection
by EMT-dependent versus EMT semi-independent assays,
and relationship to subsequent metastasis. Using both CTC
assays, we observed that highly mesenchymal PC-3M shed
CTCs very quickly post-injection and in greater numbers
than all other cell lines at most timepoints (p≤0.05)
(Figure 2A). Additionally, mesenchymal-like PC-3 shed
a similar number of CTCs as epithelial LNCaP and C42B until week 4 (EMT semi-independent assay) or week
12 (EMT-dependent assay), at which time the number
of CTCs increased significantly (p≤0.05). To quantify
differences in CTC recovery based on EMT status,
normalized CTC values obtained using both assays from
each timepoint were generated, and numbers of CTCs
identified using the EMT-dependent assay were subtracted
from numbers of CTCs identified using the EMT semiindependent assay and presented as the mean for each
timepoint. Positive values represent instances where more
CTCs were detected with the EMT semi-independent
assay, whereas negative values represent instances where
more CTCs were detected with the EMT-dependent assay
(Figure 2C). We observed that epithelial LNCaP and
C4-2B had similar CTC recovery across both assays at
all timepoints investigated. However, mesenchymal PC-3
and PC-3M showed increased numbers of CTCs recovered
using the EMT semi-independent assay at later timepoints,
with significant differences observed when comparing
PC-3 to LNCaP and C4-2B at 12 weeks (p≤0.05).

CTC recovery using the CSS is significantly
reduced for PCa cells with a mesenchymal
phenotype
As the current gold standard CTC detection
technology in the clinical setting, the CSS relies solely on
the epithelial-associated marker EpCAM for CTC capture.
However, EpCAM has been shown to be downregulated
in cells with an invasive phenotype [32], suggesting that
EpCAM-based CTC detection techniques such as the
CSS may be missing a portion of the CTCs that enter the
bloodstream. To assess this, we developed 2 novel preclinical CTC assays for use with xenograft models; one
that recapitulates EpCAM-based capture of CTCs by the
CSS (“EMT-dependent”), which captured CTCs based
on an EpCAM+/CK+/CD45-/HLA+ phenotype, and one
designed to detect all the CTCs shed into the circulation
regardless of EMT status (“EMT semi-independent”),
capturing CTCs based on a joint human HLA/EpCAM
approach, including EpCAMlow/- cells (PC-3, PC-3M;
likely captured primarily by HLA) and EpCAM+ but
HLAvariable/low cells (LNCaP, C4-2B; likely captured
primarily by EpCAM). Use of the EMT-dependent assay
resulted in significantly reduced recovery of CTCs with
mesenchymal phenotypes (PC-3/PC-3M) when compared
to CTCs with epithelial phenotypes (LNCaP/C4-2B)
(p≤0.05) (Supplementary Figure S3A). However, when
the EMT semi-independent assay was utilized, although
overall CTC recovery was lower compared to the EMTdependent assay, percent recovery was not significantly
different across cell lines regardless of EMT status
(Supplementary Figure S3B). The reduced recovery
demonstrated by the EMT semi-independent assay was
further investigated by incorporating the additional sample
handling steps required for the EMT semi-independent
assay (i.e. red blood cell lysis and additional washes) into
the EMT-dependent assay. The results demonstrated that
www.impactjournals.com/oncotarget

Prostate cancer cell lines with an increasingly
mesenchymal phenotype have enhanced capacity
for primary tumor formation and metastasis
To determine differences in the extent of disease
and metastatic spread across the 4 cells lines, at necropsy,
animals were assessed for primary tumor incidence/
weight, and metastatic spread to lymph nodes and
distant metastatic sites (lung, liver, bone). We observed
that primary tumor incidence and size was significantly
increased in highly mesenchymal PC-3M compared to all
other cell lines (p≤0.05), except when considering tumor
weight of PC-3 at 2 weeks (Figure 3A, 3B). All other cell
76128
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Figure 2: Human prostate cancer cell lines with an increasingly mesenchymal phenotype shed greater numbers of
CTCs more quickly and have an enhanced in vivo capacity for shedding CTCs that are undetectable by the CellSearch®
system. PC-3M, PC-3, LNCaP C4-2B, and LNCaP human prostate cancer cells were orthotopically injected into 6-8 week old male nude
mice via the right dorsolateral lobe of the prostate (1×106 cells/mouse) to assess spontaneous metastasis. At several timepoints post injection
(2, 4, 8, 12, and 16 weeks) mice were sacrificed and blood (100μl) was collected and processed using both the A. EMT-dependent and B.
EMT semi-independent assays (50μl/assay) to assess differences in CTC recovery. Data are presented as the mean ± SEM (n=5-12 mice/
group). C. Comparison of the observed difference in the number of CTCs detected using the EMT-dependent and EMT semi-independent
assays in matched samples. Data are presented as the mean (± SEM) difference in the number of observed CTCs between both assays (#
captured by EpCAM/HLA assay - # captured by EpCAM assay) at a given timepoint (n=5-12 mice/group). Positive values represent groups
in which more CTCs were detected with the EMT semi-independent assay, whereas negative values represent groups in which more CTCs
were detected with the EMT-dependent assay. Differences in the mean number of CTCs between cell lines at a given timepoint using and
differences between each assay within individual mice was assessed using Wilcoxon Scores followed by a Kruskal-Wallis test at each
timepoint. Comparison of differences between each assay in matched data sets within cell lines at a given timepoint was performed using a
Wilcoxon matched-pairs signed rank test. * = significant difference relative to PC-3; α = significant difference relative to LNCaP C4-2B; δ
= significant difference relative to LNCaP; γ = overall significant difference (unable to perform pairwise comparison) (p≤0.05).
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lines showed comparable primary tumor incidence and
weight at all timepoints. Additionally, primary tumor
weight and the number of CTCs shed into the circulation
(EMT-semi-independent assay) were positively correlated
for all cell lines (Figure 3C). Immunohistochemical
analysis of E-cadherin/N-cadherin revealed that all cell
lines demonstrated comparable epithelial/mesenchymal
phenotypes in vivo relative to those seen in vitro
(Figure 3D, Supplementary Figure S4A).

Additional differences between mesenchymal and
epithelial cell lines were observed in metastatic incidence
(% of mice developing metastasis) and metastatic burden
(% of organ occupied by metastatic tumor) to the lymph
nodes (LN). Microscopy analysis revealed that PC-3M
had significantly increased incidence of LN metastases
versus all other cell lines at 4 weeks (p≤0.05), while PC-3
had significantly increased incidence at 8 and 12 weeks
compared to C4-2B (p≤0.05). Interestingly, the incidence

Figure 3: Highly mesenchymal prostate cancer cells exhibit enhanced primary tumor incidence and size and in all cell
lines CTC number is correlated with primary tumor size. A. Incidence of primary tumor formation following orthotopic injection

of PC-3M, PC-3, LNCaP C4-2B, and LNCaP human prostate cancer cell lines. Data are presented as the percentage of mice per cell line
per timepoint with detectable primary tumors (n=6-39 mice/group) as assessed by microscopic histological examination of formalin-fixed,
H&E stained tissue. * = significantly different (p<0.05), ** (p<0.01), *** (p<0.001). B. Mean combined weight of prostate and bladder at
time of sacrifice following orthotopic injection of prostate cancer cell lines. Data are presented as the mean ± SEM (n=6-39 mice/group).
C. Mean normalized number of CTCs/50μl of blood (assessed using the EMT semi-independent assay) correlates with the primary tumor
weight in all cell lines. D. Representative H&E and IHC (E-cadherin and N-cadherin) images of primary prostate tumors for each cell line
(40x; scale bars = 50 μm). Primary tumor weights were assessed for cell line variances using Levene’s test, followed by a 1-way ANOVA
with Tukey’s post-test for multiple comparisons. Spearman rank correlation was utilized to examine the relationship between mean number
of CTCs and primary tumor weight. * = significant difference relative to PC-3; α = significant difference relative to LNCaP C4-2B; δ =
significant difference relative to LNCaP (p≤0.05).
www.impactjournals.com/oncotarget
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of metastases to LN did not differ significantly between
PC-3 and LNCaP (Supplementary Figure S5A). However,
PC-3 did demonstrate significantly increased metastatic
burden compared to C4-2B at 8 and 12 weeks (p≤0.05)
(Supplementary Figure S5B). Therefore, although these
cell lines appear to have a similar capacity to disseminate
to LN, they do not have the same capacity for subsequent
growth in this organ. Finally, LNCaP demonstrated
significantly increased metastatic burden compared to C42B at 12 weeks (p≤0.05). Representative H&E and IHC
analysis of LN metastases are shown in Supplementary
Figure S4B, S5C.
Differences in distant metastasis were investigated
by gross assessment at necropsy and microscopic
assessment following H&E staining. We observed that
both PC-3M and PC-3 could disseminate to and establish
gross macrometastases in a number of distant organs,
while no visible macrometastases were observed at
necropsy in mice injected with either LNCaP or C4-2B
(Figure 4). However, microscopy analysis of lung and
liver revealed distant metastases to these organs for all
of the investigated cell lines. Analysis of the incidence
of gross metastatic disease demonstrated that more
mesenchymal PC-3M and PC-3 had significantly increased
metastatic capacity versus more epithelial LNCaP and C42B (p≤0.05) (Figure 5A). Representative H&E and IHC
analysis of lung metastases are shown in Figure 5B and
Supplementary Figure S4C. Additionally, the number of
CTCs was significantly higher across all cell lines in mice
with metastatic disease relative to those without (p≤0.05)
(Figure 5C), and in those cell lines with the greatest
metastatic capacity, thus demonstrating the relationship
between CTCs and metastatic spread.

timepoints (p≤0.05), and a trend towards increasing
vimentin expression, suggesting CTCs may become more
mesenchymal as disease progresses.

DISCUSSION
CTCs have emerged as a promising biomarker for
tracking disease progression and therapy response in
patients with different types of solid tumors. However,
although CTCs are now used clinically for prognostication
in metastatic prostate, breast and colorectal cancer, their
underlying biology and the complex interplay between
EMT, CTCs and metastasis remains poorly understood.
Therefore significant debate remains with regards to which
CTCs are the most valuable to capture and characterize,
and which will serve as optimal tools for personalized
cancer treatment [33]. The lack of knowledge about CTC
biology stems from both the unique bedside-to-bench
approach employed in the CTC field and the lack of
appropriate tools for studying CTCs in vivo in pre-clinical
metastasis models.
This study aimed to address these gaps through
development of two novel pre-clinical CTC enumeration
assays and their implementation for determining
differences in CTC detection using an epithelial-based
(EMT-dependent) method and a human versus mousebased (EMT semi-independent) approach to assess the
generation of mesenchymal CTCs that would be missed
by current technologies, particularly the clinically used
CSS. Although a previous experimental study examined
CTCs in mouse models using pre-engineered, fluorescentexpressing PC-3 PCa cells [34], this is not a clinicallyrelevant scenario and thus we instead aimed to assess
CTCs using assays modeled after those used clinically.
By leveraging the capabilities of the existing CSS clinical
platform and taking advantage of the HLA complex in
separating human from mouse cells, the assays described
here are the first report of adaptation of the CSS for use
in xenograft models, without mis-identification of mouse
epithelial cells. In addition, these assays allow for the
processing/analysis very low volumes of blood (50μl),
making these assays amenable to both blood collected at
necropsy as well as serial monitoring of xenograft models
in which less than 100μl aliquots of blood can be typically
collected.
In the current study, assay validation using
sensitivity/recovery studies demonstrated that the CSSbased assay failed to detect a significant number (~4050%) of mesenchymal CTCs. In vivo, PCa tumors with an
increasingly mesenchymal phenotype shed greater numbers
of CTCs more quickly and with greater metastatic capacity
than those with an epithelial phenotype. Notably, the CSSbased assay captured the majority of CTCs shed during earlystage disease regardless of EMT status of the originating
tumor, and only after the establishment of metastases were
a significant number of undetectable mesenchymal CTCs

Circulating tumor cells acquire a more
mesenchymal phenotype during disease
progression
To further investigate the EMT profile of CTCs
shed into the circulation, blood was used to generate
CTC sub-lines representing different timepoints along
the metastatic cascade. Briefly, excess blood, not
required for CTC assessment, was lysed (NH4Cl),
washed, and resuspended in cell line specific culture
medium. Cells were cultured, with frequent media
changes to remove contaminating white blood cells,
and subsequently assessed for EMT marker expression
using immunoblotting. Unfortunately due to low
numbers of CTCs collected from LNCaP and C4-2B,
CTC growth following plating did not occur. However
several sub-lines were created for both PC-3 and PC3M. Immunoblot analysis (Figure 6) demonstrated a
significant reduction in E-cadherin expression in CTCs
collected at all timepoints compared to the parental PC-3
(p≤0.05), a trend in reduction of EpCAM expression,
a significant increase in N-cadherin expression at later
www.impactjournals.com/oncotarget
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Figure 4: Human prostate cancer cell lines with an increasingly mesenchymal phenotype have an enhanced in vivo
capacity for metastasis to distant organs. Incidence of metastasis to distant organs following orthotopic injection of PC-3M, PC-3,
LNCaP C4-2B, and LNCaP human prostate cancer cell lines. Data are presented as the percentage of mice per cell line per timepoint with
detectable distant metastases to the lung, liver diaphragm, intestines, kidney, and/or spleen/pancreas (n=7-39 mice/group) as assessed by
gross observation at necropsy (left panel) and microscopic histological examination (right panel) of tissues.
www.impactjournals.com/oncotarget
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Figure 5: Mesenchymal human prostate cancer cell lines exhibit an enhanced capacity for metastasis that is correlated
with CTC dissemination. A. Incidence of metastasis to distant organs following orthotopic injection of PC-3M, PC-3, LNCaP C4-

2B, and LNCaP prostate cancer cell lines. Data are presented as the percentage of mice per cell line per timepoint with detectable distant
metastases (n=7-39 mice/group) as assessed by gross observation at necropsy. B. Representative H&E and IHC (E-cadherin and N-cadherin)
images of lung metastases for each investigated cell line. Histological sections are presented at 40x magnification. Arrowheads on H&E
images indicate regions of tumor within the given tissue. Scale bars = 50 μm. C. Correlation of CTC number and incidence of metastasis.
Mean number of CTCs/50μl of blood, assessed using the EMT semi-independent assay, are presented for mice with either metastasis to
the lymph nodes or any distant organ (based on gross and/or microscopic analysis) or mice with no evidence of metastasis at any timepoint
(n=6-47 mice/group). Differences in the incidence of primary tumors, lymph node metastasis, and distant metastasis were assessed using
Fisher’s Exact Test. Differences in the mean number of CTCs in mice with no metastasis versus those with metastatic disease were
compared using a Student’s t-test. * = significantly different (p≤0.05), ** (p<0.01), *** (p<0.001).
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present. It is important to note that the EMT semi-independent
assay, although novel and innovative, is unfortunately not
adaptable for use with human blood samples. However,
significant effort is being focused on the development of
CTC capture techniques capable of recovering not only
CTCs expressing epithelial markers (EpCAM/CK), but also

(or even instead) those with a highly mesenchymal phenotype
[9, 10] in human specimens. This latter pursuit is based on
the idea that mesenchymal CTCs are the “bad actors”; a
hypothesis supported by experimental studies demonstrating
that EMT imparts enhanced invasiveness, metastatic
capacity, and therapy resistance [9, 10, 12]. Efforts to detect

Figure 6: Circulating tumor cells acquire a more mesenchymal phenotype during disease progression. Following

orthotopic injection of PC-3 prostate cancer cells into the right dorsolateral lobe of the prostate (1 × 106 cells/mouse) blood collected at 8
weeks, 12 weeks, and 16 weeks post-injection was lysed with sterile 1x NH4Cl, washed with PBS, and plated for tissue culture. Following
1-2 weeks of growth, with regular media changes to remove contaminating blood cells, the remaining CTCs were assessed using immunoblot
for the expression of the epithelial-associated markers E-cadherin and EpCAM and the mesenchymal-associated markers N-cadherin and
vimentin. Results are presented in quantitative densitometric form normalized to β-actin and as representative immunoblots, shown as
cropped gel images (n=3). Changes in EMT gene expression were compared to the parental cell line using 1-way ANOVA with Dunnett’s
post-test for multiple comparisons. * = significantly different than parental line (p≤0.05).
www.impactjournals.com/oncotarget
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these “bad actors” have included the exploitation of various
properties of CTCs that are either independent or less reliant
on their EMT status (e.g., size/deformability [microfiltration/
microfluidics], electrical properties [dielectrophoresis],
immunomagenetic approaches using organ/tumor specificantigens [carcinoembyronic antigen (CEA), epidermal
growth factor receptor (EGFR), prostate specific antigen
(PSA), mucin-1 (MUC-1)], and adhesion assays based on
CTCs ability to adhere to the presented capture surface)
[35]. However, our results demonstrate that although
prostate tumors with mesenchymal phenotypes shed CTCs
earlier and in greater numbers than those with epithelial
phenotypes, the majority these CTCs are still captured by
the CSS, at least before the establishment of metastatic
disease. This indicates that CTCs shed early in disease may
have a hybrid EMT phenotype during dissemination, while
still expressing sufficient levels of EpCAM and CK8/18/19
for detection using epithelial-based techniques. Therefore,
CTCs with an E-M hybrid (rather than purely mesenchymal)
phenotype may be important for establishing metastasis and
therefore most interesting to characterize, at least in earlystage patients. This is supported by observations that CTCs
with a hybrid phenotype may be of particular importance
in the clinical setting based on their EMT/MET phenotypic
plasticity [19].
Our data further demonstrates a significant increase
in the number of mesenchymal CTCs that are undetectable
by the CSS following the establishment of distant
metastases. This increase in mesenchymal characteristics
of CTCs in late-stage disease has also been demonstrated
in patients with metastatic versus localized disease [36,
37]. However, further studies are needed to determine if/
how these undetectable CTCs are contributing to disease
progression and metastasis. This is because, despite
widespread speculation, there is little evidence to support
the hypothesis that highly mesenchymal CTCs have any
additional prognostic/predictive value compared to hybrid
E-M or even purely epithelial CTCs in patients. However,
we must consider that technological limitations related
to mesenchymal CTC capture may significantly hinder
testing of this hypothesis in the clinic. In addition, we
cannot rule out the possibility that highly mesenchymal
CTCs are present in early-stage disease but not in high
enough numbers to significantly contribute to differences
between the 2 CTC assays described. In fact, the cancer
stem cell (CSC) hypothesis posits that only a fraction of
cells within the primary tumor efficiently complete the
metastatic process [38]. Therefore it is possible that the
dramatic increase in mesenchymal CTCs following the
development of metastases is due to selective outgrowth
of CSCs [39]. Thus, although this study provides valuable
insights into the role of EMT in CTC dissemination/
kinetics, many questions remain, for which the assays
developed here will be very useful in answering.
In addition to this study’s contributions towards
understanding CTC biology and its relationship to EMT, to
www.impactjournals.com/oncotarget

our knowledge it is the first comprehensive head-to-head
comparison of EMT characteristics and in vivo behavior
(including CTC dissemination/kinetics) of 4 commonly used
PCa cell lines using orthotopic injection models of PCa. It
is important to note that the metastatic process may differ
in in vivo spontaneous metastasis models in comparison
to the actual disease setting in a patient (e.g., differences
in the antigen expression/tissue architecture impacting
intravasation/extravasation, and decreased immunesurveillance in immune-compromised models) and therefore
the selection of appropriate metastasis models which best
recapitulate disease progression and dissemination is an
important consideration [40–42]. The orthotopic model
utilized throughout this study provides a much more
clinically relevant model of CTC production and metastasis
than more commonly used (and technically less challenging)
subcutaneous injection models [34]. Based upon this careful
selection, we anticipate that the data presented here will serve
as a valuable tool for future PCa research.
Overall, our pre-clinical studies provide important
translational information that will inform the use of CTCs
as valuable biomarkers of cancer progression in the clinic.
In particular, our data highlights that how CTC capture/
characterization is utilized in the clinic may greatly depend on
disease stage. Specifically, in early-stage patients where CTCs
could provide tremendous value for predicting metastasis (i.e.
adjuvant setting), detection of an increased number of CTCs
may not require technology designed to capture mesenchymal
CTCs, but instead processing of additional blood (>7.5mL)
on epithelial-based CTC technologies (e.g., CSS) may suffice
[43, 44]. In addition, our data supports the idea that primary
tumors with an increasingly mesenchymal phenotype may
have enhanced metastatic capacity and therefore the detection
of CTCs with a hybrid E-M phenotype may be of prognostic/
predictive importance in early-stage patients. In contrast,
in late-stage disease we have demonstrated a significant
increase in undetectable and highly mesenchymal CTCs
after the establishment of distant metastasis. Therefore
further research in this patient cohort will need to examine the
functional role of these CTCs versus those with an epithelial
or hybrid phenotype in disease progression and, importantly,
in therapy resistance. Taken together, the results presented
here provide novel and important insight into the functional
influence of EMT on CTC generation and metastasis in PCa.
Ultimately a better understanding of CTC biology will aid in
identifying CTCs that will be most valuable for determining
individualized treatment of metastatic cancer.

MATERIALS AND METHODS
Cell culture
LNCaP [45] (ATCC, Manassas, VA) and PC3M [46] (a gift from Paula Foster, Western University,
London, ON) human PCa cells were maintained in RPMI1640+10% fetal bovine serum (FBS). LNCaP C4-2B [47]
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[C4-2B] human PCa cells (a gift from Katherine Stemke
Hale, M.D. Anderson, Houston, TX) were maintained in
T-media+10% FBS. PC-3 human PCa cells [48] (ATCC)
were maintained in F12K media+10%FBS. MDA-MB-468
human breast cancer cells [49] (a gift from Janet Price,
M.D. Anderson) were maintained in αMEM+10%FBS.
HeLa human cervical cancer cells [50] (a gift from Jim
Koropatnick, Western University) were maintained in
DMEM+10%FBS. Media/reagents and FBS were obtained
from Life Technologies (Carlsbad, CA) and Sigma (St.
Louis, MO), respectively. Cell lines were authenticated
via third-party testing (CellCheck, IDEXX BioResearch,
Columbia, MO) in December 2015.

conjugated goat-anti-rabbit IgG secondary antibodies
(1μg; Life Technologies). Samples were analyzed using
an EPICS XL-MCL or Cytomics FC500 flow cytometer
(Beckman Coulter).

Immunofluorescence
Cells were seeded into glass chamber slides
(Thermo Scientific) pre-coated with fibronectin (5μg/mL;
Santa Cruz Biotechnologies, Dallas, TX), grown until
confluent, fixed with 2% paraformaldehyde, permeabilized
(0.1% Triton X-100; Sigma) and blocked (PBS/1% BSA;
1hr) prior to incubation with anti-E-cadherin and/or anti-αcatenin primary antibodies (1:50; 1hr). Cells were labeled
with goat-anti-mouse-IgG-AlexaFluor488 and/or goatanti-rabbit-IgG-AlexaFluor594 (Life Technologies; 1:300;
1hr) before mounting with VectaShield+DAPI (Vector
Laboratories, Burlingame, CA). Imaging was performed
(60x) using an Olympus Provis AX70 microscope
(Olympus, Richmond Hill, ON).

Real-time PCR
RNA was isolated using TRIzol (Life Technologies),
reverse-transcribed and subjected to quantitative reversetranscription polymerase chain reactions (qRT-PCR)
using Brilliant II SYBR Green qPCR Master Mix
(Agilent Technologies, Santa Clara, CA) on a Stratagene
Mx3000P (Life Technologies) (primer/cycling details;
Supplementary Table S1). Samples were normalized
using pooled qPCR human reference total RNA (Agilent
Technologies) [51].

Pre-clinical CTC assay development
Whole blood (100μL minimum) was collected
from 6-8wk old male athymic nude (nu/nu) mice (Harlan
Sprague-Dawley, Indianapolis, IN) via cardiac puncture
as described [22, 23]. Blood was processed immediately
or stored for up to 48 hours with an equal volume
of CytoChex (Streck, Omaha, NE). For CTC assay
development, 50μL of blood was “spiked” with 1000
tumor cells. To assess recovery of low numbers of cells
(5-100), serial dilutions were performed (data not shown).
The EMT-dependent CTC assay was adapted
from the Veridex mouse/rat CellCapture kit (no longer
available) as described previously [52]. Briefly, 50μL
of whole blood was incubated with components of the
CellSearch® CTC kit; including anti-EpCAM ferrofluid,
Capture Enhancement Reagent, Nucleic Acid Dye,
Staining Reagent, and Permeabilization Reagent.
Additional reagents included anti-mouse-CD45-APC
(0.30μg; 30-F11; eBioscience, San Diego, CA), and antihuman-HLA-AlexaFluor488 (1.5μg; W6/32; BioLegend,
San Diego, CA). Samples were immune-magnetically
separated and transferred to a MagNest™ for analysis
using the CSS. EpCAM+/CK+/DAPI+/CD45-/HLA+ cells
with a round/oval morphology were classified as CTCs.
Development of the EMT semi-independent CTC
assay was based on negative selection/immunodepletion of
CD45+ leukocytes combined with dual staining with human
HLA and EpCAM. Our initial assay design only employed
HLA (to take advantage of the human-in-mouse model),
however we observed that relative levels of HLA present on
each of the cell lines was highly variable, and in particular
the EpCAM+ LNCaP and C4-2B cells had low HLA
compared to PC3 cells (data not shown). Since differences
in HLA would makes interpretation of CTC capture data

Immunoblotting
Cells were harvested by cell scraping (E-cadherin,
N-cadherin) or trypsinization (vimentin, EpCAM,
α-catenin) and collected in 1% NP-40 lysis buffer.
Protein (10μg) was subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto polyvinylidene difluoride membranes
(PVDF; Millipore, Billerica, MA). Membranes were
blocked (5% skim milk in TBS-T [Tris-buffered
saline+0.1%Tween-20]; Sigma). Primary antibodies,
diluted in 5% skim milk in TBS-T are described
Supplementary Table S2. Goat-anti-mouse-IgG and
goat-anti-rabbit-IgG secondary antibodies (Calbiochem,
Billerica, MA) conjugated to horseradish peroxidase and
diluted in 5% skim milk in TBS-T were used at 1:2,000
for all proteins except E-cadherin (1:10,000). Protein
expression was visualized using Amersham ECL Prime
Detection Reagent (GE Healthcare, Wauwatosa, WI), and
normalized to total protein based on amido black (Sigma)
membrane staining.

Flow cytometry
Cells (5×105) were treated with the IntraPrep™ Fix/
Perm kit (Beckman Coulter, Fullerton, CA, USA) and
incubated with blocking buffer (PBS/5% BSA [bovine
serum albumin]); 15min). Cells were incubated with
primary antibodies (30min) as detailed in Supplementary
Table S3, followed by incubation with AlexaFluor488conjugated goat-anti-mouse IgG or AlexaFluor488www.impactjournals.com/oncotarget
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very difficult, we took a joint HLA/EpCAM approach
which detects all CTCs present, including EpCAMlow/- cells
(PC-3, PC-3M; by HLA) and EpCAM+ but HLAvariable/low
cells (LNCaP, C4-2B; by EpCAM). For testing, 50μL of
blood was lysed with NH4Cl. Samples were washed and
labeled (20min) using anti-human-HLA-PE (0.2μg; W6/32;
BioLegend), anti-human-EpCAM-PE (0.0075μg; EBA-1;
BD Bioscience), and anti-mouse-CD45-APC (0.30μg).
Samples were washed and immunomagnetically enriched
using the EasySep APC Positive Selection kit (StemCell
Technologies, Vancouver, BC). The tumor cell fraction was
incubated (20min) in Permeabilization Reagent (100μL)
and Nucleic Acid Dye (50μL; Janssen Diagnostics). After
washing, cells bound by PE-conjugated antibodies (HLA/
EpCAM) were immunomagnetically labelled using the
EasySep PE Positive Selection kit (StemCell Technologies)
and transferred to a MagNest™ for analysis using the
CSS. EpCAM/HLA+/DAPI+/CD45- cells with a round/oval
morphology were classified as CTCs.

(xylene) and rehydrated (graded series of alcohols
[100/95/80/75%]) prior to staining. Antigen retrieval was
performed (10mM sodium citrate buffer/0.05% Tween-20
[100°C; 20min]) before incubation with BLOXALL
Endogenous Peroxidase and Alkaline Phosphatase
Blocking Solution (Vector Laboratories). Staining for
E-cadherin (1:100) and N-cadherin (1:750) was performed
(Polink DS-MR-Hu kit [GBI Labs, Bothell, WA]). Slides
were imaged (40x) using an Aperio ScanScope (Aperio
Technologies, Vista CA).

In vivo CTC and metastasis assays

The authors would like to thank Benjamin Hedley
and Michael Keeney for their help and advice with
CTC assay development and flow cytometry analysis;
Madeleine Moussa for her advice with the pathohistologic
analysis; and Larry Stitt for his assistance with statistical
data analysis.

Statistical analysis
Statistical analysis was performed using GraphPad
Prism 5.0 (San Diego, CA) and/or SPSS (IBM, Armonk,
NY) as detailed in Figure Legends, with p≤0.05 considered
statistically significant.
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